Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra W Cowan-Jacob

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Current Topics in Medicinal Chemistry|July 25, 2016
Expanding the Opportunities for Modulating Kinase Targets with Allosteric ApproachesHenrik Mobitz, Wolfgang Jahnke, Sandra W Cowan-Jacob
Journal of Medicinal Chemistry|November 13, 2004
Novel purine nitrile derived inhibitors of the cysteine protease cathepsin KEva Altmann, Sandra W Cowan-Jacob, Martin Missbach
Current Opinion in Cell Biology|February 12, 2009
Structural biology contributions to tyrosine kinase drug discoverySandra W Cowan-Jacob, Henrik Möbitz, Doriano Fabbro
British Journal of Pharmacology|January 30, 2015
Ten things you should know about protein kinases: IUPHAR Review 14Doriano Fabbro, Sandra W Cowan-Jacob, Henrik Moebitz
Future Medicinal Chemistry|March 22, 2014
Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinasesSandra W Cowan-Jacob, Wolfgang Jahnke, Stefan Knapp
Biochimica Et Biophysica Acta|September 21, 2005
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemiaPaul William Manley, Sandra W Cowan-Jacob, Jürgen Mestan
Leukemia Research|October 23, 2020
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinasePaul W Manley, Louise Barys, Sandra W Cowan-Jacob
Acta Crystallographica. Section F, Structural Biology Communications|September 9, 2014
Microseed matrix screening for optimization in protein crystallization: what have we learned?Allan D'Arcy, Terese Bergfors, Sandra W Cowan-Jacob, et al.
Bioorganic & Medicinal Chemistry Letters|March 9, 2016
Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitorsFrédéric Stauffer, Sandra W Cowan-Jacob, Clemens Scheufler, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 1, 2011
Targeting cancer with small-molecular-weight kinase inhibitorsDoriano Fabbro, Sandra W Cowan-Jacob, Henrik Möbitz, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Current Topics in Medicinal Chemistry|July 25, 2016
Expanding the Opportunities for Modulating Kinase Targets with Allosteric ApproachesHenrik Mobitz, Wolfgang Jahnke, Sandra W Cowan-Jacob
Journal of Medicinal Chemistry|November 13, 2004
Novel purine nitrile derived inhibitors of the cysteine protease cathepsin KEva Altmann, Sandra W Cowan-Jacob, Martin Missbach
Current Opinion in Cell Biology|February 12, 2009
Structural biology contributions to tyrosine kinase drug discoverySandra W Cowan-Jacob, Henrik Möbitz, Doriano Fabbro
British Journal of Pharmacology|January 30, 2015
Ten things you should know about protein kinases: IUPHAR Review 14Doriano Fabbro, Sandra W Cowan-Jacob, Henrik Moebitz
Future Medicinal Chemistry|March 22, 2014
Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinasesSandra W Cowan-Jacob, Wolfgang Jahnke, Stefan Knapp
Biochimica Et Biophysica Acta|September 21, 2005
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemiaPaul William Manley, Sandra W Cowan-Jacob, Jürgen Mestan
Leukemia Research|October 23, 2020
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinasePaul W Manley, Louise Barys, Sandra W Cowan-Jacob
Acta Crystallographica. Section F, Structural Biology Communications|September 9, 2014
Microseed matrix screening for optimization in protein crystallization: what have we learned?Allan D'Arcy, Terese Bergfors, Sandra W Cowan-Jacob, et al.
Bioorganic & Medicinal Chemistry Letters|March 9, 2016
Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitorsFrédéric Stauffer, Sandra W Cowan-Jacob, Clemens Scheufler, et al.
Methods in Molecular Biology (Clifton, N.J.)|October 1, 2011
Targeting cancer with small-molecular-weight kinase inhibitorsDoriano Fabbro, Sandra W Cowan-Jacob, Henrik Möbitz, et al.
Pageof 4